Cargando…
Comparison of Hypomethylator Monotherapy with Hypomethylator plus Chemotherapy for Intermediate/High-Risk MDS or AML: A Meta-Analysis
Aim: This meta-analysis aimed to compare the efficacy, survival benefit and safety of hypomethylating agents (HMA) monotherapy and combination with chemotherapy in patients with intermediate/high-risk MDS or AML. Methods: Related articles published between January 2009 and April 2019 were selected a...
Autores principales: | Ji, Jiang, Chen, Miao, Han, Bing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7086269/ https://www.ncbi.nlm.nih.gov/pubmed/32226512 http://dx.doi.org/10.7150/jca.40614 |
Ejemplares similares
-
Risk of infection in elderly patients with AML and MDS treated with hypomethylating agents
por: Livio, Pagano, et al.
Publicado: (2018) -
Beyond the Edge of Hypomethylating Agents: Novel Combination Strategies for Older Adults with Advanced MDS and AML
por: Kubasch, Anne Sophie, et al.
Publicado: (2018) -
Clinical Results of Hypomethylating Agents in AML Treatment
por: Cruijsen, Marjan, et al.
Publicado: (2014) -
Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL‐2 and/or BIM
por: Huemer, Florian, et al.
Publicado: (2019) -
Treatment of Low-Blast Count AML using Hypomethylating Agents
por: De Bellis, Eleonora, et al.
Publicado: (2017)